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outcome of the Temporary Authorization for Use
programme in France
Nadine Houédé1,2*, Philippe Beuzeboc3, Sophie Gourgou4, Diego Tosi5, Laura Moise6, Gwenaëlle Gravis7,
Remy Delva8, Aude Fléchon9, Igor Latorzeff10, Jean-Marc Ferrero11, Stéphane Oudard12, Sophie Tartas13,
Brigitte Laguerre14, Delphine Topart15, Guilhem Roubaud16, Hanane Agherbi2, Xavier Rebillard17 and David Azria2,18Abstract
Background: COU-AA-301 trial has proved that abiraterone acetate (AA), a selective inhibitor of androgen biosynthesis,
improved overall survival (OS) of patients with metastatic castration resistant prostate cancer (mCRPC) after a first line of
docetaxel. Based on this result, a Temporary Authorization for Use (TAU) was performed between December 2010 and
July 2011 to provide patients with mCRPC the opportunity to receive AA before its commercialization. The aim of this
study was to evaluate safety and efficacy of AA treatment in this TAU.
Methods: Between December 2010 and July 2011, we conducted an ambispective, multicentric cohort study and
investigated data from 20 centres participating to the AA TAU for patients presenting mCRPC and already treated by a
first line of chemotherapy (CT). Statistical analyses of the data were performed using the Stata software v13 to identify
predictive and prognostic factors.
Results: Among the 408 patients, 306 were eligible with a follow-up at 3 years. Median OS was 37.1 months from beginning
of CT and 14.6 months from AA introduction. 211 patients (69%) received≥ 3 months of AA and 95 patients (31%) were
treated less than 3 months. In the multivariate analyses, duration of AA was significantly correlated with PSA decrease at
3 months. Additionally, shorter time under AA treatment, presence of multiple sites of metastasis and previous hormonal
treatment duration were three independent factors associated with poorer OS. At the time of analysis ten patients were
still under treatment for more than 3 years.
Conclusions: Biochemical response monitored by PSA changes at 3 months is a strong predictive factor for AA treatment
duration. Some high responders’ patients could beneficiate from AA for more than 3 years.
Keywords: Metastatic castration-resistant prostate cancer, Abiraterone acetate, Efficacy, Prognostic factorBackground
Management of metastatic castration-resistant prostate
cancer (mCRPC) has dramatically changed over the past
5 years [1]. Until 2011, the standard of care in first line
was the addition of docetaxel, a tubulin poison chemo-
therapy (CT), to LHRH analogue considering that hor-
monal treatments alone are no longer efficient in this* Correspondence: nadine.houede@chu-nimes.fr
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unless otherwise stated.setting [2]. As second line treatment, the only published
phase III trial compared the use of cabazitaxel, another
tubulin poison, to mitoxantrone after progression and
led to the approval of cabazitaxel [3].
New paradigms have emerged in the last decade with ini-
tial studies showing that Abiraterone Acetate (AA) may re-
verse hormonal resistance by specifically inhibiting 17 α-
hydroxylase/C17,20 lyase (CYP17A1) involved in the an-
drogen synthesis pathway [4]. Indeed, CYP17A1 is
expressed in testicular, adrenal and prostatic tumor tissues,
which explain why mCRPC tumor growth still relies onl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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door” pathway of androgen synthesis and may result in a
drastic decrease of testosterone circulating levels [5]. In that
context, the phase III trial COU-AA-301 demonstrated a
significant overall survival benefit of AA/prednisone com-
pared to placebo/prednisone (14.8 vs 10.9 months) [6].
In the meantime, France was one of the first countries
to make AA available to mCRPC patients after docetaxel
CT through a Temporary Authorization for Use (TAU).
This type of program allowed patients to have access to
the drug from the time of European Medicines Agency
approval and the reimbursement approval by the French
National Health Services.
In December 2010, we undertook an observational
study evaluating safety and long-term efficacy of AA in
the daily clinical practice.
Methods
Data collection
The French Agency for National Medical Security
allowed patients with mCRPC that progressed during or
after docetaxel, to access AA before its commercial
availability from December 2010 to September 2011.
This ambispective observational cohort study was con-
ducted in 20 centres that accepted to record AA safety
and efficacy data for all their patients enrolled in the
TAU.
Data collection was done on site from medical records
of all the TAU patients. Data were updated in April 2014.
Ethics statements
This study was approved by the French data protection
authorities (CNIL) and the Comité Consultatif sur le
Traitement de l’Information en matière de Recherche
dans le domaine de la Santé (CCTIRS # 11.545 approved
on September 29th 2011). Written informed consent
was waived because this is a retrospective study. The
study was undertaken in accordance with the ethical
standards of the World Medical Association Declaration
of Helsinki.
Patients and treatment
Inclusion criteria were as follows: men with mCRPC and
documented disease progression during or after a
docetaxel-containing regimen. Progression was defined by
clinical progression, PSA progression and/or radiographic
progression on bone scan or CT scan, as defined by the
Prostate cancer Working Group 2 (PCWG2) criteria [7].
Patients should be under androgen deprivation and had
castration level of testosterone (<50 ng/ml). Before AA de-
livering, patients should had potassium level >3.5 mmol/l,
ASAT/ALAT <5 UNL in case of liver metastasis, or <2.5
UNL in the absence of metastases, and total bilirubin <1.5
UNL. Regarding the toxicity profile, exclusion criteriaincluded uncontrolled hypertension, severe or unstable
angina, and myocardial infarction within 6 months, heart
failure, arterial or venous thromboembolic events, or clin-
ically significant ventricular arrhythmias.
The recommended dose of AA was 1 g per day, as 4
tablets of 250 mg in one administration one hour before
or two hours after a meal, in combination with oral
prednisone 5 mg twice a day. Patients were treated until
clinical, biological or radiological progression according
to PCWG2 criteria, death, unacceptable toxicity, or phy-
sician’s or patient’s decision to stop the treatment.
Outcomes measures
In the context of this TAU, clinical and biological
follow-up were scheduled every 15 days within the first
three months of treatment and monthly afterwards until
treatment discontinuation. Radiological evaluation dur-
ing follow-up was not mandatory. All selected variables
were collected in the medical report i.e. patients’ charac-
teristics, disease description at diagnosis (Gleason score,
tumour classification, metastasis sites before chemother-
apy and before AA, PSA kinetics, number of prior doce-
taxel cycles, duration of treatments and reasons for
treatment discontinuation), and follow-up.
For the efficacy analysis, survival time were calculated in
two different manners: from the beginning of CT, defined
as the time interval between the start of first line chemo-
therapy and the date of death; and from the initiation of
AA and the date of death. Patients alive were censored at
the last known follow-up date. AA treatment duration
was classified in three categories (≤3 month, 3–6 months,
and > 6 months), according to the biological and radio-
logical assessment planned in the TAU program, and in
two categories (≤3 month, >3 months) for multivariate
analysis. PSA was measured at the time of inclusion, at 3
and 6 months as suggested in the TAU. Adverse events
were followed on a monthly basis and graded according to
the NCI-CTCAE v3.0.
Statistical methods
Qualitative variables were described by frequency of mo-
dalities and percentage. Continuous variables were de-
scribed by mean, median, and range. Data are presented
with 95% confidence intervals (95% CI), calculated with
the use of exact methods based on the binomial distribu-
tion for discrete variables.
Median follow-up was calculated with the use of the
Kaplan-Meier reverse method.
Predictive factors of AA treatment duration (in two cat-
egories: ≤3 month, >3 months) were identified with the
use of univariate and multivariate logistic regression using
a backward selection method, including the following vari-
ables: age, Gleason score, duration of CT before AA treat-
ment, baseline PSA, PSA before AA treatment, site of
Table 1 Patients’ characteristics and pre-AA history





4 - 6 33 (10.8%)
7 92 (30.0%)
8 - 10 134 (43.8%)
missing 47 (15.4%)
Sites of metastasis before CT
Bone only 144 (47.1%)








Sites of metastasis before AA
Bone only 127 (41.5%)








PSA before CT (ng/mL) Median [range] Missing
45.4 [0–4967] 37 (12.1%)
PSA before AA (ng/mL) Median [range]
121.2 [0.15 - 8322] 13 (4.2%)
Hormone treatment duration (months) Median [range]
31.6 [0–201]
CT treatment duration if one line (months) Median [range
4.9 [0.3-20.7]
CT treatment duration if more than 1 line (months) Median [95% CI]
6.2 [0 – 50.2]
Lines of CT before AA Median [range]
1 [1-5]
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Table 1 Patients’ characteristics and pre-AA history (Continued)
4 10 3.3
5 3 1.0






First line CT after AA (if applicable) N %
Cabazitaxel 51 30.6
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hormone therapies, and number of CT lines.
Overall survival rates were estimated using the
Kaplan–Meier method.
A Cox proportional-hazards model was used to esti-
mate the hazard ratios indicating the effects of prognos-
tic factors on the risk of death. Three and 6 months
landmark analyses were performed to explore the associ-
ation between duration of AA treatment and overall
survival.
All tests were two-sided, with a P value of less than
0.05 considered as statistically significant. Analyses were
performed using the Stata software, v13.
Results
Patients
Up to September 2011, 408 patients were enrolled in the
initial study. Complete follow-up data were obtained for
306 patients in 13 centres from the 20 initially selected
centres and were considered for this report. Seven cen-
tres did not want to pursue this observational study.
Median follow-up from the initiation of AA is
36.3 months (95%CI 35.8-37.1). Descriptive data at the
time of AA introduction are included in Table 1. Patients’
characteristics were collected at inclusion. Median (range)
age was 63 years (46–82). Before starting AA, 41.5% of the
patients had bone metastasis only, 9.8% visceral metastasis
only, and 48.7% showed multiple sites. Median duration of
hormone therapy before chemotherapy was 31.6 months
[0–201]. Before starting AA, all patients received at least
one line of CT. For most of them, CT was based on doce-
taxel alone or in combination (298 patients, 97.4%). One
hundred seventy (55.6%) patients received only oneprevious line of CT, 103 (33.7%) two lines, 20 (6.5%) three
lines, 10 (3.3%) four lines, and three patients (1%) received
five lines. For the patients receiving only one line, median
duration of CT was 4.9 months [0–24]. Hundred sixty
nine patients (55%) received at least one line of CT post
AA treatment (Table 1).
Efficacy
Treatment duration
Median duration of AA treatment was 5.2 months
(0.03-34.1).
A total of 211 (69%) patients received more than 3 months
of AA and 10 patients were still under treatment at the time
of the last follow-up visit (April 2014) with a median (range)
duration of 36.5 months (32.9-38.9) (Table 2).
Overall survival
OS from the beginning of CT and from the initiation of AA
were 37.1 months (95% CI 32.5- 39.7) and 14.6 months
(95% CI 12.6- 16.5), respectively. OS was significantly asso-
ciated with the duration of AA (P < 0.001) in both the
3 months and 6 months Landmark analyses (Figure 1A & B).
Biological response
In the overall population, median PSA value at baseline
was 121.2 ng/ml [0.15-8322], 87.8 ng/ml [0–5001] at
month 3, and 79 ng/ml[0–5600] at month 6. A subgroup
analysis was performed to assess PSA changes between
baseline and month 3 for patients receiving <3 months
(97 patients) and > = 3 months (211 patients) of AA treat-
ment (Figure 2). The results show that the PSA response
for patients who were treated more than three months by
Figure 1 Overall survival from the beginning of Abiraterone Acetate for the three categories of patients (treatment duration ≤3 months,
[3,6], >6 months). (A) 3 months Landmark analysis. (B) 6 months Landmark analysis.
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who were treated less than three months (Figure 2).
One hundred eighty five patients (60.4%) received one to
three treatments following AA: cabazitaxel for 64 patients
(21.7%), rechallenge docetaxel (n = 60, 20.3%), enzalutamide
(n = 31, 10.5%), cyclophosphamide (n = 27, 9%), mitoxan-
trone (n = 24, 8.1%), and estramustine (n = 13, 4.4%).Table 2 Treatment duration of Abiraterone Acetate
Months N %
≤ 3 85 27.8
]3-6] 84 27.4
>6 127 41.5
Ongoing treatment 10 3.3At the time of the last follow-up visit (April 2014) 10
patients, treated in 4 different centres, were still under
AA. For this long-term responder subpopulation, me-
dian age was 65 years [54–78]; Gleason score at the be-
ginning of AA was 6 for two patients, 8 for five patients
and 9 for one patient, missing data for 2 patients. All of
them had bone metastases but four presented concomi-
tant visceral metastases. Median PSA value was 33 ng/
ml [0.15-231] at baseline, 3.4 ng/ml [0.14-170] at month
3, and 1.34 ng/ml [0.15-231] at month 6.
Safety
Most common adverse events were hypokalaemia (n =
16 but grade ≥3 for 2 patients), hypertension (n = 9 but
grade ≥3 for 1 patient), hepatic and liver dysfunction
Figure 2 Changes of PSA values between baseline (blue boxes)
and 3-months (red boxes) for patients receiving <3 months (left
panel) or > = 3 months (right panel) of AA. The dots correspond
to extreme values of PSA levels.
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safely administered with only seventeen adverse events
resulting in treatment discontinuation. Treatment was
discontinued for 274 (89.5%) patients because of dis-
ease progression. Among them, 26 patients (9%) died
from their disease and three patients (1%) died from










PSA baseline before CT Continuous variable
PSA baseline before AA Continuous variable
Sites of metastasis Bone or visceral alone vs Multiple




PSA variation at 3 months Decrease
IncreasePredictive and prognostic factors
Landmark analyses included 264 patients followed for more
than 3 months and 233 patients followed for more than
6 months.
In univariate analysis, predictor of duration of AA treat-
ment was PSA changes between the start of AA and the
3 months time point (P < 0.0001). The multivariate ana-
lysis confirmed a longer AA treatment in case of PSA de-
crease under treatment (OR 0.13, P < 0.0001) (Table 3).
Three factors were found to be associated with poorer
OS following univariate analysis: multiple sites of metas-
tasis (versus bone metastasis alone) (P =0.025), previous
hormonal treatment duration (less than 70 months;
75th percentile) (P =0.001) and duration of AA treat-
ment (less than 3 months) (P < 0.001). Similar results
were obtained in the multivariate analysis with the fol-
lowing significant associations: multiple sites of metas-
tases (P =0.019, HR 1.41 [95% CI 1.05-1.88]), first line
hormonal treatment duration (P =0.001, HR 0.54 [95% CI
0.38-0.77]) and duration of AA treatment (P <0.001, HR
0.55 [95% CI 0.39-0.77]) (Table 4).
Discussion
This ambispective observational cohort study enrolled
all the eligible mCRPC patients of the 20 centres which
agreed to participate. This was rapidly followed by the
prescription of AA by other centres leading to a nationalUnivariate analysis Multivariate analysis
OR p OR p
1 0.107
0.57 95% CI [0.29-1.13]
1
1.24 95% CI [0.45-3.39] 0.68
1.16 95% CI [0.44-3.05] 0.76
1
0.99 95% [0.42-2.31] 0.98
2.00 95% [0.81-4.98] 0.13
1.17 95% [0.53-2.59] 0.70
0.99 95% [0.99-1.00] 0.10
1.00 95% [0.99-1.00] 0.67
1 0.17 1
0.65 95% CI [0.36-1.19] 0.71 95% [0.35-1.44] 0.34
1
1.02 95% [0.53-1.99] 0.94
1.23 95% [0.33-4.56] 0.75
0.26 95% [0.02-4.34] 0.35
1 <0.0001 1
0.06 95% [0.02-0.19] 0.13 95% [0.06-0.31] <0.0001
Table 4 Pronostic factors of overall survival (Cox model)
Univariate analysis Multivariate analysis
HR p HR p
Gleason score 4-6 1
7 1.54 95% CI [0.91-2.60] 0.11
8-10 1.63 95% CI [0.98-2.72] 0.06
Nb CT line 1 1
2 1.17 95% CI [0.86-1.60] 0.309
3 1.09 95% CI [0.59-2.03] 0.785
4 1.11 95% CI [0.52-2.39] 0.788
5 0.81 95% CI [0.11-5.82] 0.835
Sites of metastasis Bone or visceral alone vs Multiple 1 0.025 1 0.019
1.38 1.41
95% CI [1.04-1.83] 95% CI [1.05-1.88]
Previous hormonal treatment duration Less than 70 months vs More than 70 months 1 0.001 1 0.001
0.55 0.54
95% CI [0.39-0.79] 95% CI [0.38-0.77]
Duration of AA treatment Less than 3 months vs More than 3 months 1 <0.001 1 <0.001
0.52 0.55
95% CI [0.38-0.74] 95% CI [0.39-0.77]
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months. When the TAU was initiated, no other treat-
ment was available besides docetaxel or experimental
treatments accessible in clinical trials. Therefore, a high
number of patients were allowed to receive AA treat-
ment. Consequently, the population of this study is a
“real-life”, non-selective population that includes a large
number of patients with advanced disease (48.7% with
multiple sites of metastases) who received up to 5 lines
of chemotherapy.
In terms of safety, the pivotal COU-AA-301 study
demonstrated that AA was associated with elevated min-
eral corticoids levels, aminotransferase level affecting
liver function, urinary tract infections, fluid retentions,
and oedema [6]. In our study, a high proportion of in-
cluded patients presented an advanced disease, but no
new adverse event was recorded, confirming the safety
of AA usage.
Median treatment duration was three months shorter
than the one observed in the COU-AA-301 trial (5 ver-
sus 8 months). Though patients were more heavily pre-
treated and the duration of treatment by AA was much
shorter, we did not observe a significant change in OS
(14.6 months in the present study versus 14.8 months in
the COU-AA-301). In concordance with the OS that is
observed from the introduction of first line CT, it may
reflect the evolution of care in the management of
mCRPC patients.
We found that the duration of AA treatment was sig-
nificantly associated with prolonged survival. Two thirdof the patients received more than 3 months of AA,
whereas the other third received less than 3 months of
AA, indicating that these patients rapidly developed a
resistance to the drug. This resistance is mainly due to
an alteration of the androgen receptor (AR) axis by sev-
eral mechanisms including changes in AR expression
levels, occurrence of AR mutations, interactions of AR
with co-activators or co-repressors, or increase in the
expression of the CYP17A1 target itself [8]. In these pa-
tients, a fatal issue is rapidly observed despite the use of
cabazitaxel or of the AR antagonist enzalutamide. Indeed,
several retrospective studies showed that enzalutamide
had modest clinical activity in patients with mCRPC who
previously received docetaxel and AA [9,10]. For patients
where resistance is due to an overexpression of CYP17A1,
it is however possible to envisage an increase in AA dos-
age in order to prolong survival [11].
Prior to our study, the only relevant predictive factor
of response to AA was the baseline level of testosterone
as determined in the post hoc exploratory analysis of
COU-AA-301 data, the OS being significantly longer in
patients with high androgen levels [12,13]. Interestingly,
we found that the main predictive factor of AA benefit
was the difference in PSA values between baseline and
3 months of treatment. PSA flare up described previ-
ously concerns a minority of patients (less than 10%)
[14], so determination of PSA levels could help the early
monitoring of AA benefit and avoid maintaining an inef-
fective costly treatment. When localized to the bone
only, presence of metastases was a good prognostic
Houédé et al. BMC Cancer  (2015) 15:222 Page 8 of 9factor significantly associated with prolonged OS. A
former retrospective analysis with 116 patients treated
with AA at the Princess Margaret Hospital in Toronto
showed that bone localisation could impact PSA re-
sponse [15] further strengthening our current observa-
tion. We also report for the first time that duration of
hormonal sensitivity was associated with prolonged sur-
vival following AA treatment, asking the question
whether AA should be prescribed for patients with par-
ticularly high levels of resistance to hormonal therapy.
Recent studies have shown new options for the treat-
ment of mCRPC: the use of AA as first line treatment in
chemo-naïve patients [13] or the use of enzalutamide as
first [16] or second line [17] treatment. However, there
is no study evaluating the different possible sequences
with the three drugs that are currently approved or going
to be approved as first line treatment. Preclinical data
showed impaired efficacy of docetaxel and cabazitaxel in
abiraterone-resistant prostate cancer cell lines [18]. These
data were reinforced by clinical studies evidencing a lower
activity of docetaxel in patients pre-treated with AA
[19,20]. Thus, the question of AA positioning in terms of
clinical benefit in a chronic disease where patients could
live up to 3 years remains open. The results of our study
tend to suggest that using AA post docetaxel is an excel-
lent option with a median OS of 37 months.
Conclusions
Our study provides new information for current clinical
practice by showing that patients with progressive dis-
ease within the first 3 months of AA treatment will
probably present short overall survival. It further shows
the utility of a strong monitoring of the PSA changes
that could act as an early predictive marker of this clin-
ical benefit and may encourage physicians to switch rap-
idly to other therapies. Results of other on-going
observational studies are awaited to confirm which pa-
tients could beneficiate the most from AA [21].
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